FINHUB Insights

GILD · Q1 FY25 · Jan 1 – Mar 31, 2025

Gilead Sciences Q1 FY25: where the revenue came from and where it went

Gilead Sciences Q1 FY25: revenue $6.7B (+0% year over year). Net profit $1.3B. Largest cohort HIV Products Biktarvy $3.2B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jan 1 – Mar 31, 2025
Reported
May 7, 2025 10-Q
Sankey diagram of Gilead Sciences's income statement for Q1 FY25: revenue of $6.7 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$6.7B +0% year over year
Gross profit$5.1B 77% margin
Operating profit$2.2B 34% margin
Net profit$1.3B 20% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Mar 31, 2025).
ItemValueShare of revenueYear over year
Revenue 6.7 100% +0%
HIV Products Biktarvy 3.2 48% +7%
Other 1.2 18%
HIV Products Descovy 0.6 9% +38%
Yescarta 0.4 6% +2%
HIV Products Genvoya 0.4 6% −10%
Liver Disease Products Sofosbuvir… 0.3 4%
Veklury 0.3 4%
Trodelvy 0.3 4% −5%
Cost of revenue−1.522%
Gross profit5.177% margin+0pp
SG&A−1.319%−2pp
Other−1.624%+0pp
Operating profit2.234% margin+98pp
Tax−0.3
Interest & other costs−0.6
Net profit1.320%+82pp
Filing on EDGAR More quarters of GILD

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters